Skip to main content
VCYT logo

Veracyte, Inc.

VCYTNASDAQHealthcareDiagnostics & Research

$44.39Today:- (-)1Y +23.96%

As of Oct 15, 2026 close

Market cap
$3.64B
P/E (TTM)
31.82
Forward P/E
15.73
Dividend yield
-
52-week range
$29.46$60.91
Volume (live)
-
Avg. volume (3M)
1.37M

Veracyte (VCYT) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Veracyte reported total assets of $1.41B and total liabilities of $96.44M. Shareholders' equity was $1.31B, up 11.4% from $1.18B a year earlier. Total debt stood at $39.65M against $412.89M in cash and short-term investments, a net cash position of $373.24M. That puts debt-to-equity at 0.03, compared with 0.04 a year earlier.

Veracyte Balance Sheet Analysis

Values in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Veracyte, Inc. (VCYT) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Current Assets
Cash and Cash Equivalents0.360.240.220.150.170.350.160.080.03
Short-Term Investments0.050.050.000.020.000.000.000.000.00
Cash & Short-Term Investments0.410.290.220.180.180.350.160.080.03
Accounts Receivable0.040.050.040.040.040.020.020.010.01
Inventory0.020.020.020.010.010.000.010.000.01
Other Current Assets0.010.010.010.010.010.000.000.000.00
Total Current Assets0.490.370.290.250.240.380.190.100.05
Non-Current Assets
Property, Plant & Equipment (Net)0.060.070.030.030.030.020.020.010.01
Long-Term Investments0.000.000.000.000.000.000.000.000.00
Goodwill0.770.750.700.700.710.000.000.000.00
Intangible Assets0.090.100.090.170.200.060.070.010.01
Other Non-Current Assets0.000.010.010.010.000.000.000.000.00
Total Non-Current Assets0.920.930.830.910.940.080.090.020.02
Total Assets1.411.301.111.161.190.460.280.120.08
Current Liabilities
Accounts Payable0.000.010.010.010.010.000.000.000.00
Short-Term Debt0.000.010.010.000.000.000.000.000.00
Current Portion of Long-Term Debt----0.00----
Accrued Liabilities0.020.010.040.040.010.01---
Deferred Revenue0.000.000.000.000.000.000.000.000.00
Other Current Liabilities0.000.060.040.010.000.010.010.010.01
Total Current Liabilities0.060.080.060.060.060.020.020.010.01
Non-Current Liabilities
Long-Term Debt0.040.040.010.010.010.010.010.020.03
Deferred Tax Liabilities0.000.000.000.000.010.000.000.000.00
Other Non-Current Liabilities0.000.000.000.010.010.010.010.000.00
Total Non-Current Liabilities0.040.050.010.020.030.020.020.030.03
Total Liabilities0.100.120.070.080.090.040.040.040.04
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.000.000.00
Retained Earnings-0.38-0.44-0.47-0.39-0.36-0.28-0.25-0.23-0.21
Accumulated Other Comprehensive Income-0.01-0.04-0.02-0.03-0.020.000.00-0.01-0.01
Additional Paid-in Capital1.701.661.541.501.470.700.490.310.25
Shares Outstanding0.080.080.070.070.07----
Total Stockholders' Equity1.311.181.041.081.100.420.240.080.04
Total Liabilities & Equity1.411.301.111.161.190.460.280.120.08

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Veracyte Balance Sheet

How much debt does Veracyte have?

Veracyte had total debt of $39.65M as of Dec 31, 2025, against $412.89M in cash and short-term investments. Its debt-to-equity ratio was 0.03. Total debt was $50.74M a year earlier.

What are Veracyte's total assets?

Veracyte reported total assets of $1.41B as of Dec 31, 2025, up 8.2% from $1.30B a year earlier. Total liabilities were $96.44M.

What is Veracyte's shareholders' equity?

Veracyte's shareholders' equity was $1.31B as of Dec 31, 2025, or about $16.50 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition